» Articles » PMID: 26936280

MicroRNA-141 and Its Associated Gene FUS Modulate Proliferation, Migration and Cisplatin Chemosensitivity in Neuroblastoma Cell Lines

Overview
Journal Oncol Rep
Specialty Oncology
Date 2016 Mar 4
PMID 26936280
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study, a novel signaling pathway of microRNA-141 (miR-141)/fused in sarcoma (FUS) was investigated in neuroblastoma (NB). Gene expression of miR-141 was evaluated in 6 NB cell lines. IMR-32 and SH-SY5Y cells were transduced with the miR-141 mimic lentivirus. The effects of miR-141 upregulation on cell proliferation, cell division, migration, chemosensitivity and in vivo explants were evaluated by MTT, cell cycle, wound-healing, cisplatin sensitivity and in vivo tumor growth assays, respectively. The correlation between miR-141 and the FUS gene was evaluated by luciferase assay and qRT-PCR. FUS was also downregulated in IMR-32 and SH-SY5Y cells to evaluate its impact on NB regulation. miR-141 was downregulated in both MYCN‑ and non-MYCN‑amplified NB cell lines. In the IMR-32 and SH-SY5Y cells, lentivirus-induced miR-141 upregulation inhibited cancer proliferation, cell cycle progression, migration and increased cisplatin chemosensitivity in vitro. In addition, miR-141 upregulation reduced the in vivo growth of IMR-32 tumor explants. FUS was found to be inversely regulated by miR-141 in NB. Small interfering RNA (siRNA)-induced FUS downregulation had similar tumor-suppressive effects as miR-141 upregulation on NB cell proliferation, cell cycle progression, migration and cisplatin chemosensitivity. Our data indicate that miR-141 and the FUS gene, which are inversely correlated, play significant functional roles in regulating human NB.

Citing Articles

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.

Pucci P, Lee L, Han M, Matthews J, Jahangiri L, Schlederer M Nat Commun. 2024; 15(1):3422.

PMID: 38653965 PMC: 11039739. DOI: 10.1038/s41467-024-47771-x.


LMNTD2-AS1 regulates immune cell infiltration and promotes prostate cancer progression by targeting FUS to regulate NRF2 signal pathway.

Wu H, Liu N, He A, Li H, Liu H, Qian J Am J Cancer Res. 2023; 13(8):3384-3400.

PMID: 37693143 PMC: 10492130.


Role of non-coding RNAs in neuroblastoma.

Anoushirvani A, Jafarian Yazdi A, Amirabadi S, Ahmadi Asouri S, Shafabakhsh R, Sheida A Cancer Gene Ther. 2023; 30(9):1190-1208.

PMID: 37217790 DOI: 10.1038/s41417-023-00623-0.


Expression of IL-13Rα2 and FUS in glioma: clinicopathological and prognostic correlation.

Cheng G, Wang M, Zhang X, Zhang Y BMC Neurol. 2023; 23(1):185.

PMID: 37158824 PMC: 10165843. DOI: 10.1186/s12883-023-03237-z.


The role of miR-200 family in the regulation of hallmarks of cancer.

Klicka K, Grzywa T, Mielniczuk A, Klinke A, Wlodarski P Front Oncol. 2022; 12:965231.

PMID: 36158660 PMC: 9492973. DOI: 10.3389/fonc.2022.965231.


References
1.
Das S, Bryan K, Buckley P, Piskareva O, Bray I, Foley N . Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs. Oncogene. 2012; 32(24):2927-36. PMC: 3477279. DOI: 10.1038/onc.2012.311. View

2.
Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N . Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol. 2011; 32(3):583-8. DOI: 10.1007/s13277-011-0154-9. View

3.
Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

4.
Brodeur G . Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003; 3(3):203-16. DOI: 10.1038/nrc1014. View

5.
Tsuda T, Obara M, Hirano H, Gotoh S, Kubomura S, Higashi K . Analysis of N-myc amplification in relation to disease stage and histologic types in human neuroblastomas. Cancer. 1987; 60(4):820-6. DOI: 10.1002/1097-0142(19870815)60:4<820::aid-cncr2820600418>3.0.co;2-y. View